Marketing: Page 70
-
High specialty drug prices help drive renewed spike in 2014 healthcare spending
Although overall health spending increased by 5.3% in 2014, the rate of growth was still much slower than in previous years.
By Nicole Gray • Dec. 4, 2015 -
Martin Shkreli's big regret: Not pricing Daraprim even higher
During an intense exchange with Forbes' Matt Herper, the outspoken pharma exec doubled down on his position, arguing that a 5,000% increase for the drug wasn't enough and making the case that shareholder return always comes first.
By Nicole Gray • Dec. 4, 2015 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma DiveTrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Pharma's PR problem: 53% of Americans blame pursuit of profits for high drug prices
And more than 70% of those polled did not believe the prices of branded prescription drugs were reasonable.
By Nicole Gray • Dec. 2, 2015 -
US Senate report slams Gilead over Sovaldi price, insinuates culture of profits over patients
The report reveals that Medicaid programs spent $1.3 billion in 2014 (before rebates) on Gilead drugs to treat only 2.4% of enrollees with hepatitis C. But the company is pushing back against the narrative—hard.
By Nicole Gray • Dec. 2, 2015 -
Express Scripts banishes Turing from formulary, turns to compounder for generic Daraprim
The largest pharmacy benefits manager (PBM) in the U.S. is partnering with Imprimis for a $1-per-pill Daraprim (pyrimethamine) option.
By Nicole Gray • Dec. 2, 2015 -
Deep Dive
World AIDS Day: PrEP uptake main hurdle to 2030 eradication goal as Obama unleashes action plan
The president on Tuesday outlined a federal action plan for tackling HIV/AIDS which endorsed full access to PrEP for at-risk individuals. Will his remarks help increase use of the controversial therapy?
By Nicole Gray • Dec. 1, 2015 -
How China is getting serious about developing quality drugs right at home
As Chinese biopharma companies experience substantial growth, China hopes to further foster a domestic drug market.
By Nicole Gray • Dec. 1, 2015 -
What's driving the rapid rise in dermatology drug prices?
Prices for branded prescription dermatology products increased 500% over six years, according to a recent study.
By Nicole Gray • Nov. 30, 2015 -
In blow to Sanofi/Regeneron, CVS favors Amgen's competing PCSK9 med for its formulary
Once CVS Health determined that Repatha and Praluent were therapeutically equivalent, it became all about price negotiations.
By Nicole Gray • Nov. 24, 2015 -
Pharma advertising powerhouse is born with Pfizer, Allergan megamerger
Pfizer alone spent $1.4 billion in measured media last year in the U.S.
By David Kirkpatrick • Nov. 24, 2015 -
Deep Dive
How biopharma companies can thrive in the era of megamergers and shrinking budgets
We spoke with James Crowley at Accenture Life Sciences about what it takes to not only survive, but to shine, in a hyper-competitive market.
By Nicole Gray • Nov. 24, 2015 -
Annual cost of specialty drugs surpasses median household income
An AARP Policy Institute report aims to highlight the financial impact of soaring drug costs even though the insured don't pay retail prices.
By Heather Caspi • Nov. 23, 2015 -
Samsung Bioepis close to major EU approval for Enbrel biosimilar
The European Medicines Agency recommended approval of Benepali, heating up the biosimilar market for Enbrel.
By Nicole Gray • Nov. 23, 2015 -
Deep Dive
Why marketers think they'll win in doctors' new war on DTC drug ads
The American Medical Association's proposed ban on direct-to-consumer prescription drug ads threatens to end a $4.5B ad category and is being slammed by pharma companies, and particularly marketers.
By Natalia Angulo • Nov. 20, 2015 -
Big pharma trying to quash CA drug price cap effort with massive campaign war chest
J&J, AbbVie, Amgen, Eli Lilly, and BMS all have contributed to a fund aimed at defeating the "California Drug Price Relief Act."
By Nicole Gray • Nov. 20, 2015 -
IMS 2020 forecast: Drug spending will hit a whopping $1.4 trillion
The spike in spending will be driven by increased uptake in emerging markets and the impact of high-priced specialty drugs, according to the group.
By Nicole Gray • Nov. 19, 2015 -
Early scripts for female libido pill Addyi fall flat, Valeant left holding the bag
Only 227 Addyi (flibanserin 100 mg) prescriptions were dispensed in the first few weeks post-launch, and the hits just keep coming for Valeant.
By Nicole Gray • Nov. 19, 2015 -
In unexpected setback, UK cost regulators reject Amgen's PCSK9 drug
The National Institute for Health and Care Excellence (NICE) decided against including Repatha (evolocumab) on the UK's list of reimbursable drugs due to concerns about cost-effectiveness and clinical outcomes.
By Nicole Gray • Nov. 19, 2015 -
Paris attack forces Isis Pharma to again consider name change
The problem is self-evident, but the company is hesitant to give up a brand name that took 25 years to build.
By Nicole Gray • Nov. 18, 2015 -
AMA backs ban on direct-to-consumer pharma ads
The group says ads drive patients to seek more expensive treatments even when lower-cost options are available.
By Nicole Gray • Nov. 18, 2015 -
Deep Dive
NEJM joins the fray in drug pricing debate as 2 thought leaders share divergent perspectives
Dr. William W. Chin and Dr. Peter Bach are experienced thought leaders with important positions in the biopharma and medical communities—and they have very different opinions about drug pricing and healthcare sustainability.
By Nicole Gray • Nov. 16, 2015 -
Horizon swipes back at Express Scripts as PBM cuts off drugmaker's specialty pharma
According to Express Scripts, Linden Care Pharmacy mainly dispensed Horizon drugs and did not fulfill the network agreement. The PBM has also filed suit against Horizon.
By Nicole Gray • Nov. 12, 2015 -
AHF: Gilead's new HIV med an attempt to evergreen, avoid patent expiration
Does tenofovir's new, improved side-effect profile make Genvoya a new drug, or just a tweaked version of Stribild?
By Nicole Gray • Nov. 11, 2015 -
No 'purple pill' for Dr. Reddy's—court sides with AZ, blocks Nexium generic over coloration
A Delaware district court ruled in favor of the British pharma giant and its trademark infringement claims.
By Sy Mukherjee • Nov. 10, 2015 -
Allergan asks SCOTUS to take a hard look at pharma's controversial 'hard switch' tactic
The company lost in federal court when attempting to pull its Alzheimer's med Namenda in order to force patients over to a new formulation. If the Supremes take the case, it would have industry-wide implications for antitrust laws.
By Nicole Gray • Nov. 10, 2015